7th Nov 2018 12:04
LONDON (Alliance News) - Skin health-focused life science company SkinBioTherapeutics PLC on Wednesday reported positive results from the first two parts of its SkinBiotix human study focusing on skin irritancy and moisturisation potential.
In the skin irritation study, a cream containing SkinBiotix was applied to 30 healthy subjects in five doses of different concentration, which was assessed at 24, 48 and 72 hours following application. There were no instances of skin irritation in any of the subjects.
On a longer term test, 31 healthy subjects were subjected to five doses of the cream, keeping it in contact for 12 days. For 15 days, the volunteers were monitored for signs of irritation, with only one experiencing irritation.
For the moisturisation potential study, 21 subjects had been applied with SkinBiotix cream, with the moisture content of the skin measured for up to 12 hours. The cream was revealed to have generally higher moisturisation than provided by the control cream, however the difference was not significant.
SkinBiotix will move on the third and main element of the human study, which will involve 120 volunteers with self-assessed dry skin, to analyse the longer term moisturisation effects and impact on skin barrier function of the SkinBiotix technology.
The third study is expected to take place in November.
"Demonstrating that SkinBiotix is a safe technology is a major milestone for the company and, as with many cosmetics, allows for commercialisation of a product. The irritation study results validate the safety element of our technology and provide further reasons for potential partners to speak to us," said Chief Executive Catherine O'Neill.
Shares in SkinBioTherapeutics were flat at 18.50 pence on Wednesday.
Related Shares:
Skinbiotherap.